Immunothérapie : Libre accès
Libre accès

Abstrait

CDK5RAP3 as A Novel Biomarker Signature Predicting Survival and Adjuvant Chemotherapeutic Benefit in Gastric Cancer

Chao-Hui Zheng, Jian-Wei Xie, Jia-Bin Wang, You-Xin Gao, Ning-Zi Lian, Ping Li, Jian-Xian Lin, Jun Lu, Qi-Yue Chen, Long-Long Cao, Mi Lin, Li-Chao Liu, Ru-Hong Tu, Ju-Li Lin, Ze-Ning Huang, Hua-Long Zheng, Yu-Bin Ma

Objective: To examine the clinical significance of CDK5RAP3 to predict chemotherapeutic responsiveness in gastric cancer.

Background: We previously demonstrated that CDK5RAP3 acts as a tumor suppressor in gastric cancer through negative regulation of the Wnt/β-catenin signalling pathway, but its function in chemotherapeutic responsiveness of gastric cancer has not been investigated.

Method: A collection of 188 pairs of tumour tissue microarray specimens from Fujian Medical University were employed for the discovery set, and 310 tumour tissue samples of gastric cancer patients were employed for the internal validation set. Eight-five tumour tissue samples from Qinghai University Hospital were used as the external validation set 1. Transcriptomic and clinical data of 299 gastric cancer patients from TCGA were used as the external validation set 2. CDK5RAP3 expression, microsatellite instability (MSI) status, and tumour-infiltrating lymphocytes (TIL) were examined with immunohistochemistry. Clinical outcomes of patients were compared with Kaplan-Meier curves and the Cox model.